SCHEMBL5855166

SCHEMBL5855166

CCOC(=O)Cn1c(Cl)cnc(NC(CN)Cc2ccccc2)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 2/20 0.41
AURKA O14965 2/20 0.41
RPS6KB1 P23443 2/20 0.41
TSHR P16473 2/20 0.41
F2 P00734 4/20 0.41
PRSS1 P07477 3/20 0.41
LMNA P02545 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP3A4 P08684 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.39
PRSS2 P07478 1/20 0.38
PRSS3 P35030 1/20 0.38
ADORA3 P0DMS8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5855156 1.00 MEN1 (0.47) MEN1KMT2AALDH1A1KDM4EAURKA
SCHEMBL5855365 0.89 MEN1 (0.46) MEN1KMT2AALDH1A1KDM4ETSHR
SCHEMBL5855369 0.89 MEN1 (0.46) MEN1KMT2AALDH1A1KDM4ETSHR
SCHEMBL7254246 0.83 MEN1 (0.41) MEN1KMT2AALDH1A1KDM4ETSHR
SCHEMBL7254244 0.83 MEN1 (0.41) MEN1KMT2AALDH1A1KDM4ETSHR
SCHEMBL7257930 0.83 MEN1 (0.41) MEN1KMT2AALDH1A1KDM4ETSHR
SCHEMBL7257933 0.83 MEN1 (0.41) MEN1KMT2AALDH1A1KDM4ETSHR
SCHEMBL5855244 0.77 F2 (0.41) MEN1KMT2AKDM4EF2PRSS1
SCHEMBL5855236 0.77 F2 (0.41) MEN1KMT2AKDM4EF2PRSS1
SCHEMBL5482299 0.77 F2 (0.49) MEN1KMT2AALDH1A1KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026324-B2 Thrombin inhibitors MERCK & CO., INC. (US) 2006-04-11 US disclosed
US-20040097730-A1 Thrombin inhibitors MERCK & CO., INC. 2004-05-20 US disclosed
EP-1359913-A1 THROMBIN INHIBITORS Merck & Co., Inc. (US) 2003-11-12 EP disclosed
WO-2003011222-A2 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2003-02-13 WO disclosed
WO-2002064140-A1 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097730-A1 Thrombin inhibitors F3, F2, SERPINC1 MEN1 1529/4885KMT2A 3143/4885ALDH1A1 3936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.